anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (bric a brac, tramtrack, broad complex / pox virus zinc finger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involved oncogene in diffuse large B-cell lymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice. DLBCLs are aggressive tumors that arise from germinal center (GC) B- cells and are the most common form of non-Hodgkin&#39;s lymphomas. BCL6 is required for survival of DLBCL cells and can limit their ability to respond to DNA damaging agents. It is also frequently expressed in follicular lymphomas (FLs), and may be required for survival of these tumors as well. DLBCL and FL collectively constitute ∼60-70% of B-cell lymphomas and the incidence of these tumors has been rising in recent decades.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new percutaneous absorbefacient improving the absorption of a medicine through the skin when the medicine is applied as an external agent.  &lt;P&gt;SOLUTION: This percutaneous absorbefacient contains a fruit of Evodia rutaecarpa or an extract thereof. The percutaneous absorbefacient of a non- steroid antiinflammatory agent contains the fruit of the Evodia rutaecarpa or the extract thereof. The percutaneous absorbefacient of an acidic antiinflammatory agent contains the fruit of the Evodia rutaecarpa or the extract thereof. The percutaneous absorbefacient of an indole acetate-based antiinflammatory agent contains the fruit of the Evodia rutaecarpa or the extract thereof. The percutaneous absorbefacient of indomethacin, sulindac and acemetacin contains the fruit of the Evodia rutaecarpa or the extract thereof.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
PROBLEM TO BE SOLVED: To judge and evaluate the stimulus development under the application of light of a makeup decoration by using a specific amount of peroxide being generated at sebum by applying light under the coexistence with the sebum. SOLUTION: A makeup decoration is mixed into sebum or its similar matter, light such as ultraviolet rays is applied to it and the amount of generated peroxide is measured, thus using the amount of generated as an index. More specifically, the sebum is obtained by gathering naturally secreted sebum or using skin as it is and collecting sebum after applying light. In the case of the skin, human skin is preferable, and a plurality of panelers are used to reduce personal difference. The foundation or the like of a specimen are applied to the specimen on the sebum by 0.01 g/30 cm&lt;2&gt; , and the quantity of light to be applied is set with the amount of ultraviolet rays being matched to the conditions of solar light for easily creating peroxide as an index.  After light is applied, a sebum constituent is collected from a site by a solvent, the peroxide valence is measured, and lesser TBA value in reference to 55 is evaluated as less development of stimulus.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition comprising a concoction of tea and Peucedanum Japonicum Thunb. or an extract from the concoction, where excellent functions of Peucedanum Japonicum Thunb. and tea are combined so as to highly exert synergistic health effect.  &lt;P&gt;SOLUTION: The composition is obtained by the following process: pulverizing, rolling, fermenting and drying leaves or stalks of tea (especially green tea) to obtain a tea concoction; extracting the tea concoction with a solvent to obtain a tea extract; at the same time, pulverizing and drying the roots or leaves of the Peucedanum Japonicum Thunb. to obtain a Peucedanum Japonicum Thunb. concoction; extracting the Peucedanum Japonicum Thunb. concoction with a solvent or subjecting the concoction to steam distillation to collect an essential oil to obtain Peucedanum Japonicum Thunb. extract; and mixing the tea concoction or the tea extract with the Peucedanum Japonicum Thunb. concoction or the Peucedanum Japonicum Thunb. extract. The composition is utilized as a beverage or drinking tea leaves, or formulated with various kinds of foods to be utilized.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a &#34;do not eat me&#34; signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common &#34;do not eat me&#34; signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.
Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the present invention, without limitation, satisfy either Formula (1) or Formula (2). Currently preferred compounds, based on in vivo biological activity, are 4&#39;adamantylbenzoate-1&#39;-N-1,4-dihydroxybenzylamine and 4&#39;-adamantylmethylbenzoate-1&#39;-N-1,4-dihydroxybenzylamine. The present invention also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs. Such compositions also may comprise other active ingredients, other materials conventionally used in the formulation of pharmaceutical compositions, and mixtures thereof. The compounds and compositions of the present invention can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.
Multidrug resistance to anti-tuberculous drugs poses threat in the treatment of tuberculosis. These strains are resistant to at least tow first line anti-tuberculous drugs such as INH and rifampicin. Frequently, such MDR strains show resistance to all commonly used first-line agents i.e INH, rifampicin, streptomycin, ethambutol and pyrazinamide. Isoniazid is the most widely used anti-tuberculous drug. Resistance to isoniazid can occur by increased expression on inhA or by mutations that lower the enzyme&#39;s affinity to NADH. Mutations in katG, which encodes catalase peroxidase, is the most common source of resistance. Another mechanism of isoniazid resistance occurs by defects in NADH dehydrogenase (Ndh) of the respiratory chain. Increases expression of AhpC has been suggested as another mechanism of INH resistance in mycobacteria. The present invention provides method of treating drug resistance for Mycobacterium tuberculosis infection. According to present invention, a method is provided to employ penicillin with INH. This reduces the MIC of INH and makes resistant organisms sensitive. The level of penicillins required for reversal of INH resistance is known to be achieved and maintained by therapeutic doses of penicillins.
Device, system and method, for simplicity call Big Data 911™, which expedites response times after vehicle accidents or other emergencies. It automatically initiates a 911 computer call from a vehicle and/or a phone with data comprising GPS data location, speed, etc., Caller ID and the person&#39;s preapproved medical history all of which is continuously linked to the cloud before and/or after the crash. This data indicates when a crash and/or other emergency-occurs using speed, acceleration and deceleration and other data. Multiple sources of data when available offers redundancy to verify data and avoid unnecessary 911 calls. It expedites transportation to the hospital and ensures the optimum medical treatment customized for the victim during the crucial Golden Hour after the accident. This solution can be used nationally or internationally using Big Data in worldwide networks which track billions of phones and/or vehicles.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition having the excellent adiponectin-production induction action.  &lt;P&gt;SOLUTION: The composition is provided which contains the chalcon and isoflavone of Angelica keiskei. This composition takes an effect of the excellent adiponectin-production induction action, consequently the composition is useful in the fields of foods and medicines, especially useful for the prophylaxis, improvement and/or medical treatment of fatness and fatness-resultant lifestyle diseases such as circulatory diseases (arteriosclerosis, hyperlipemia, etc.) and diabetes, etc. Moreover, there is provided a method for producing such an extract derived from Angelica keiskei as contains the chalcon of Angelica keiskei with a high concentration.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Abstract of the Disclosure Systems and methods to assist an emergency medical dispatcher in responding to emergency calls are disclosed. A computer-implemented emergency dispatch protocol is provided that includes interrogatories for a dispatcher to ask a caller to generate an appropriate response. A diagnostic tool is provided to aid a dispatcher in determining a likelihood that the patient has meningitis. The diagnostic tool determines a likelihood that the patient has meningitis based on caller-relayed information concerning the caller&#39;s observations of the patient. The diagnostic tool can be launched automatically by the emergency dispatch protocol, or manually, as desired by a dispatcher. The diagnostic tool presents a user interface that may provide, among other things, questions to guide the caller in identifying signs and symptoms that the patient has meningitis and input components associated with the questions. 11664200_1 (GHMatters) P93806.AU.2 ,IPr*QAtDiagnosticToolsW1II I bb &#34;rworsAdcibonzi n I atkns Viaing -Meningitis Dx Indicatars Prgress -314 TtsPositive Answers cricaI Single Crteri 316 312- El MiorCrteia El - ormentRtmt K 2
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair caring agent and a skin caring agent curing damaged hair or roughened skin and keeping hair and skin in a good state with more moistness, luster and tenseness than those of the conventional agents in caring for the hair and skin.  &lt;P&gt;SOLUTION: The hair caring agent and skin caring agent are characterized as follows. Rosin is dissolved in ethanol and purified water is then added to provide a rosin emulsion. A colloidal aqueous solution of a polymeric cassia β-glucan is obtained by carrying out extraction and purification from complex polysaccharides derived from a plant. The resultant rosin emulsion is mixed with the colloidal aqueous solution and sodium sulfite.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
A method of gene therapy is described that will protect the hearts of patients against myocardial infarction. Antioxidant enzymes are known to be cardioprotective, provided that these enzymes are administered before reperfusion. However, it has not previously been practical to administer antioxidant enzymes to patients at risk for myocardial infarction because the recombinant enzymes were expensive and required continuous intravenous administration. These limitations have been overcome by using gene therapy to provide a continuous source of antioxidant enzyme. When tested in carefully controlled pre-clinical studies, antioxidant gene therapy reduced the size of myocardial infarction by &gt;50%. This marked reduction in infarct size could mean the difference between life and death for many patients, and would improve the quality of life for every person that survived myocardial infarction. This same approach may also be used by cardiothoracic surgeons to improve the functional recovery of donor hearts after cardiac transplantation.
The present invention discloses heparinase I fusion protein and encoding genes and an expression method thereof. The heparinase I fusion protein provided by the present invention is protein having an amino acid residue sequence of SEQ ID No. 2 in a sequence table or protein which has the same activity as that of the amino acid residue sequence of the SEQ ID No. 2, is derived from the SEQ ID No. 2 and is formed by means that the amino acid residue sequence of the SEQ ID No. 2 is replaced, deleted or added by one or a plurality of amino acid residues. The present invention is characterized in that more than 90% of the heparinase exists in escherichia coli in the modes of activity and correct folded soluble protein. The heparinase activity can achieve 270 U/L in fermentation liquid (108UL &lt;-1&gt; OD&lt;600&gt;&lt;-1&gt;), and the content of the protein can achieve 150 mg/L. In addition, the single step purification of the fusion protein is realized by compatible separation. The present invention can be widely used for producing the heparinase I.
Condensation products of a tetracycline with HCHO and an amine of formula RNH.Z.SO2X where R = H, alkyl or hydroxyalkyl (is not &gt;C4); Z = CH2 or CH2CH2; X = OH when Z = CH2 or X = H or SH when Z = CH2CH2. Compounds are of undetermined structure. &#34;NEW&#34; but tetracyclines are specified as cycline and 7-chloro-6-demethyltetracycline. Stable derivs. having high water solubility useful for oral or parenteral admin. The acute and chronic toxicities are lower than those of the parent tetracycline or their known derivs. The compounds do not cause fatty degeneration of the liver to such a great extent as the parent tetracyclines. Amine: HCHO : tetracycline in ratio 1:1:1 to 1:3:2.
PURPOSE:To obtain a cosmetic having low stickiness, by compounding pyrrolidonecarboxylic acid, etc., and a crude extract derived from peel of Lansium domesticum Jack var. Duke, etc. and lansic acid, etc., which are components of the extract. CONSTITUTION:The objective cosmetic is produced by compounding (A) 0.05-1wt.% (in terms of lansic acid) one more more substances selected from crude extract obtained from peel of Lansium domesticum jack var. Duke of Lansium domesticum Jack var. Lancer, lansic acid and lansioside which are components of the extract and their derivatives and (B) 0.05-10% one or more substances selected from pyrrolidonecarboxylic acid (salt), hyaluronic acid (salt) and water-soluble polyols having &gt;=2 OH groups in the molecule (e.g. propylene glycol). The cosmetic activates the function of dermatic cell and exhibits remarkable effect to protect and beautify the skin.
PCT No. PCT/JP87/00021 Sec. 371 Date Aug. 31, 1987 Sec. 102(e) Date Aug. 31, 1987 PCT Filed Jan. 14, 1987 PCT Pub. No. WO87/04434 PCT Pub. Date Jul. 30, 1987.This invention provides an indenothiazole derivative and a process for manufacturing the same. The said indenothiazole derivative is represented by the following formula: &lt;IMAGE&gt; (Ia)  wherein X and Y are identical with, or different from, each other and are each a hydrogen atom, halogen atom, low alkyl group or low alkoxy group; n is an integer of from 0 to 4; R1 is a hydrogen atom, low alkyl group, unsubstituted or substituted phenyl group; R2 is a low alkyl group, cycloalkyl group, low alkoxyl group, unsubstituted or substituted phenoxy group, unsubstituted or substituted phenyl group, alkenyl group, heterocyclic group or cycloamino group; R3 is a hydrogen atom, low alkyl group or acyl group; and R2 and R3 may be combined to form a cycloamino group. Further, this invention also provides a tautomer of the compound represented by the above formula (Ia), wherein all the symbols are as defined above except that R3 is limited to a hydrogen atom.
The present invention relates to a medicinal liquor-cangchunjiu liquor for curing diabetes, impotence, rheumatism, anorexia and other diseases. It is made up by using 30-old Chinese medicinal materials of valvet deerhorn, deer&#39;s testis and penis, seal&#39;s genitals, ginseng, sea horse, lycium berry, cordyceps and others, and its preparation method includes the following steps: drying all the materials, pulverizing, soaking them in liquor to make extraction, heating and concentrating extract and using condenser to recover white liquor. The temp. of extraction is 50-70 deg.C, extraction time is 24-48 hr., extraction frequency at least is three times, and the temp. of concentration is 85-100 deg.C, when the temp. is quick risen above the set control value the concentration step is stopped. After the extract is filtered, the filtered extract is stored in metering tank, according to calculation a part of the extract is taken out, and concentrated, then the concentrated medicated liquor can fed back into metering tank, and mixed with other extract to regulate alcohol content. Its production efficiency is high, and its medicine content is high.
The invention discloses an AEG-1 (Astrocyte Elevated Gene-1)/1E3 monoclonal antibody with high affinity. The amino acid sequence of a variable region of a light chain of AEG-1/1E3mAb is shown as SEQ ID. NO. 1, and the amino acid sequence of a variable region of a heavy chain is shown as SEQ ID. NO. 2. The uniqueness for the gene sequence and corresponding protein sequence of a variable region of the antibody and CDR (Complementary Determined Region) sequence of the antibody are determined; the AEG-1/1E monoclonal antibody has high affinity with AEG-1, and the AEG-1 can be specifically identified and immunological reaction can be performed; and the titer of ascites is 1*10&lt;-7&gt;. Support is provided for researching and developing anti-AEG-1 gene engineering antibody and a diagnostic reagent.
PURPOSE:To produce a superoxide dismutase (SOC), by reacting the SOC with a copolymer containing specific group as constitutional units and having a specific average mol. wt. in an aqueous solution of alkali having pH 7-11. CONSTITUTION:A superoxide dismutase is reacted with a copolymer containing a group such as formula I (R&lt;1&gt; is H or methyl and R&lt;2&gt; is H, Cl, Br or methyl group), group expressed by formula II (R&lt;7&gt; is H, 1-4C alkanol, etc.) and group expressed by formula III as constitutional units and having 800-20,000 average mol. wt. in an aqueous solution having pH 7-11 to provide the SOD derivative. The derivative is expressed by formula IV (SOC is a superoxide dismutase having 1-6 groups excluding one H from amino group; Z is the above-mentioned formula I; X is integer of 1-6).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a therapeutic agent for use in inducing angiogenesis and vasculogenesis.  &lt;P&gt;SOLUTION: The therapeutic agent includes angiogenesis- and vasculogenesis-inducing factors isolated from stem cells in conjunction with a pharmaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis- and vasculogenesis-inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of angiogenesis- and vasculogenesis-inducing factors is provided. Angiogenesis- and vasculogenesis-inducing factors isolated and purified from stem cells for use in a therapy is provided. The method for obtaining the angiogenesis- and vasculogenesis-inducing factors as set forth above, and the process include the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture-expanding the mesenchymal stem cells to produce a tool for neurological and musculoskeletal therapy. Isolated and culture-expanded mesenchymal stem cells under the influence of a requisite compound can differentiate and produce a desired cell phenotype needed for tissue repair.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The present invention belongs to the technical field of health care wine, particularly to a cordial for nourishing bodies, which is made from rose and Chinese caterpillar fungus. The cordial is prepared from two production methods, and has a technological process: screening and cleaning of raw materials, ingredient leaching, clarification and filtration, blending and ageing, checking and fine filtration, filling and stabilization, and checking for obtaining the cordial. The raw materials for producing the cordial comprises edible wine, rose, raspberry, dandelion, pawpaw, honeysuckle flower, chrysanthemum flower, ganoderma and aweto, wherein the edible wine is white wine and yellow wine. The present invention has one method that the raw materials are leached together, and has the other method that the ganoderma and the aweto are separated and leached by the edible wine. The alcoholicity of the wine is from 6 to 45%&lt;v&gt;/v. The present invention provides a novel cordial for nourishing bodies for the society, has the functions for promoting qi, activating blood circulation to dissipate blood stasis, expulsing toxin and keeping youthfulness, and has the advantages of simple and convenient production technology, easy control, less investment, low production cost, and good economical and social benefit.
The present invention relates to an indapamide dripping pill and a preparation method thereof. The dripping pill is prepared from indapamide and base materials in the proportion by weight of 0.625 to 10:39.375 to 30, wherein the base materials are selected from one or two of polyethylene glycol 6000, polyethylene glycol 4000, polyethylene glycol 2000, polyethylene glycol 1500, polyethylene glycol 1000, poloxamer, span 40 and stearic acid. The indapamide dripping pill of the present invention is prepared by solid dispersion technology, compared with tablets, the adjuvant dosage is correspondingly decreased than that of the tablets so that the dissolution, the absorption and the action of the indapamide dripping pill are rapid in liquid, and the indapamide dripping pill has the advantages of high bioavailability and high stability. In addition, the volume of the indapamide dripping pill is small so that the indapamide dripping pill can be swallowed by a user or kept in the user&#39;s mouth and is convenient for carrying. Accordingly, the indapamide dripping pill is especially suitable for old people, bedridden patients and patients with dysphagia to take. The present invention has the advantages of simple method, technology and production device and low production cost, and is suitable for mass productive preparation.
PURPOSE:To produce a soft capsule agent made of gelatin and having high hardness and stability comparable to those of conventional soft capsule agents using oils, by filling an aqueous liquid of sugars having higher concentration than a specific level, as a principal agent. CONSTITUTION:A soft capsule agent made of gelatin can be produced by filling an aqueous liquid of sugar (e.g. sucrose, glucose, fructose, maltose, etc.) having a concentration of &gt;=55w/w% as a principal agent. The present soft capsule is characterized by the use of an aqueous liquid in place of oil organic solvent which gives unagreeable feeling when chewed by mistake and is disadvantageous also in view of the production cost. The hardness and stability of the present soft capsule having a sugar concentration of &gt;=55w/w%, especially &gt;=65w/w% are comparable to those of the conventional soft capsules produced by using an oil as the solvent of the objective content. An aqueous liquid containing an organic acid or its salt as well as the sugar can also be filled in the capsule. Concrete examples of the content are ascorbic acid, riboflavin, plum pulp extract, etc.